# KANJINTI® (trastuzumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/trastuzumab

> The FDA approved KANJINTI® (trastuzumab), sponsored by BioNTech SE (BNTX), on August 4, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | KANJINTI® (trastuzumab) |
| Codes |  |
| Sponsor | BioNTech SE (BNTX) https://sec-api.dev/companies/bntx/catalysts |
| Indications | [advanced endometrial cancer](https://sec-api.dev/indications/advanced-endometrial-cancer), her2-positive unresectable or metastatic breast cancer, her2-expressing advanced solid tumors |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### Jan 2024: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: HER2-expressing advanced solid tumors.
- First seen 2025-09-05, last confirmed 2025-09-05.
- Press release filed with the SEC (EX-99) (accession 0001776985-25-000055): "In January 2024, the partners initiated a global Phase 3 DYNASTY-Breast02 trial program for trastuzumab pamirtecan in HR-positive, HER2-low metastatic breast cancer (DYNASTY-Breast02, NCT06018337) following positive Phase 1/2 safety and efficacy data in patients with HER2-expressing advanced solid tumors." https://www.sec.gov/Archives/edgar/data/1776985/000177698525000055/a99120250905_bnt323xdb-130.htm

### Sep 2025: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: advanced endometrial cancer.
- First seen 2025-11-03, last confirmed 2025-11-03.
- Press release filed with the SEC (EX-99) (accession 0001776985-25-000065): "-In September 2025, the first patient was dosed in a Phase 3 trial (NCT06340568) to evaluate trastuzumab pamirtecan compared to investigator's choice of chemotherapy in patients with advanced endometrial cancer." https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm

### September 5, 2025: interim data readout

- Status: completed, met. Date confidence: exact. Stage: 3. Indication: HER2-positive unresectable or metastatic breast cancer.
- First seen 2025-09-05, last confirmed 2025-09-05.
- Press release filed with the SEC (EX-99) (accession 0001776985-25-000055): "MAINZ, Germany and SHANGHAI, China, September 05, 2025 - BioNTech SE (Nasdaq: BNTX, "BioNTech") and Duality Biologics (Suzhou) Co., Ltd. ("DualityBio") today announced that the pivotal Phase 3 trial (NCT06265428) which DualityBio is conducting in China to evaluate trastuzumab pamirtecan (BNT323/DB-1303) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and a taxane-based chemotherapy met its primary endpoint of progression free survival at a pre-specified interim analysis." https://www.sec.gov/Archives/edgar/data/1776985/000177698525000055/a99120250905_bnt323xdb-130.htm

### 2026: NDA/BLA submission

- Status: scheduled. Date confidence: year.
- First seen 2026-08-04, last confirmed 2026-08-04.
- Press release filed with the SEC (EX-99) (accession 0001776985-26-000054): "•While BioNTech and DualityBio plan to file a biologics license application ("BLA") in 2026, the companies will determine the optimal regulatory path for trastuzumab pamirtecan based on the totality of clinical data in endometrial cancer and breast cancer." https://www.sec.gov/Archives/edgar/data/1776985/000177698526000054/a991bntx_q22026pressreleas.htm

### August 4, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Stage: 3.
- First seen 2026-08-04, last confirmed 2026-08-04.
- Press release filed with the SEC (EX-99) (accession 0000078003-26-000094): "Announced FDA approval of Ibrance in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) locally advanced or metastatic breast cancer (MBC) following induction treatment based on data from the collaborative Phase 3 PATINA trial." https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/trastuzumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KANJINTI® (trastuzumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/trastuzumab

```bibtex
@misc{secapidev_pdufa_trastuzumab_20261116,
  title        = {KANJINTI® (trastuzumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/trastuzumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_trastuzumab_20261116","title":"KANJINTI® (trastuzumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/trastuzumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
